ConductScience.org, home

Paper31420554

Atherosclerosis.

Libby P and 7 others. Nat Rev Dis Primers, 2019. Cited by 2,562 papers, by iCite.

Cite this record

ConductScience Library. Atherosclerosis. Papers, record 31420554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31420554

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Atherosclerosis.
PubMed
Journal
Nat Rev Dis Primers
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
2,562
iCite
Relative citation ratio, by iCite
120
iCite
Revised in PubMed
2020-07-06
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Libby PPeter
2Buring JEJulie E
3Badimon LLina
4Hansson GKGöran K
5Deanfield JJohn
6Bittencourt MSMárcio Sommer
7Tokgözoğlu LLale
8Lewis EFEldrin F

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AtherosclerosisMajor topic
Drug Therapy
Humans
Hyperlipidemias
Mass Screening
Risk Factors

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 HL080472NHLBI NIH HHSUnited StatesR01HL080472PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07520643MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular SignalingBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by1,832

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,562 citations.

PMIDTitleJournalYearIn PapersSource
42985392Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects.Int J Nanomedicine2026https://conductscience.org/library/papers/42985392PubMed
42983283Routine metabolic-adiposity indices and incident cardiometabolic multimorbidity among adults with CKM stages 0-3: a prospective cohort study.BMC Cardiovasc Disord2026https://conductscience.org/library/papers/42983283PubMed
42978991Design, Synthesis, and CETP Inhibitory Evaluation of Novel P-methoxybenzene Sulfonamides Supported by Molecular Modeling.Iran J Pharm Res2026https://conductscience.org/library/papers/42978991PubMed
42964405Circulating Interleukin-36 Alpha, Beta, Gamma, and Interleukin-37 Levels in Patients With Chronic Coronary Syndrome.Cardiol Res2026https://conductscience.org/library/papers/42964405PubMed
42961710Predictive and risk stratification performance of CCTA-derived pericoronary adipose tissue radiomics for major adverse cardiovascular events: retrospective development and prospective validation.Radiol Med2026https://conductscience.org/library/papers/42961710PubMed
42957434PAK4 as a cardiometabolic node: tissue-specific metabolic control, cardiovascular remodeling, and therapeutic trade-offs.Korean J Physiol Pharmacol2026https://conductscience.org/library/papers/42957434PubMed
42955221MUSE-Net: a SegFormer-B2-based multi-expert ensemble for multicenter carotid plaque segmentation in ultrasound images.Med Biol Eng Comput2026https://conductscience.org/library/papers/42955221PubMed
42948745Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis.Acta Pharm Sin B2026https://conductscience.org/library/papers/42948745PubMed
42942436PAD as a Marker of Systemic Atherosclerosis: A Comprehensive Review of Residual Risk and Contemporary Strategies for MACE and MALE Reduction.Medicina (Kaunas)2026https://conductscience.org/library/papers/42942436PubMed
42939664Modulating the NLRP3/IL-1β Axis in Age-Related Atherosclerosis: Natural Products, Molecular Mechanisms, and Translational Perspectives-A Narrative Review.Biomolecules2026https://conductscience.org/library/papers/42939664PubMed
42939023BMA-Net: A Bilateral Attention Network with Retinal Domain Transfer-Learning for CIMT-Based Cardiovascular Risk Classification from Fundus Images.Bioengineering (Basel)2026https://conductscience.org/library/papers/42939023PubMed
42929811SUMOylation as a Stress-Responsive Rheostat in Cardiovascular Disease.Cells2026https://conductscience.org/library/papers/42929811PubMed
42928775Targeting Metabolic Drivers of Cardiovascular Disease: Insights for Therapeutic Innovation.Drug Des Devel Ther2026https://conductscience.org/library/papers/42928775PubMed
42924604Inflammatory regulatory mechanisms and targeted therapy of antineutrophil cytoplasmic antibodies in atherosclerosis (Review).Int J Mol Med2026https://conductscience.org/library/papers/42924604PubMed
42923720Vascular aging biomarkers: the role of ADMA, SDMA, and inflammation.Front Cardiovasc Med2026https://conductscience.org/library/papers/42923720PubMed
42920854Macrophage-directed cardiovascular nanomedicines: Linking pharmaceutical design with cell state, lesion niche, and intracellular function.Int J Pharm X2026https://conductscience.org/library/papers/42920854PubMed
42909371Cell-derived biomimetic nanomedicines: Emerging theranostic platforms for precision management of atherosclerosis.Theranostics2026https://conductscience.org/library/papers/42909371PubMed
42909347Targeted molecular CT imaging of atherosclerosis and abdominal aortic aneurysm.Theranostics2026https://conductscience.org/library/papers/42909347PubMed
42905940NSG Mice Lacking Apoe: An Immunodeficient Mouse Model of Atherosclerosis.FASEB J2026https://conductscience.org/library/papers/42905940PubMed
42903377Role of insulin resistance in atherosclerosis: underlying mechanisms and emerging stem cell-based therapeutic strategies.Front Med (Lausanne)2026https://conductscience.org/library/papers/42903377PubMed

See all 1,832 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31420554

GET https://conductscience.org/api/papers/v1/31420554/cited_by?page=2